Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q2 | Jun 30, 2025 | Clark Street Value | - | -3.6% | ACR, ATHA, CKX, CMCT, CRGX, EHAB, EPIX, GRBK, HLVX, HMST, IGT, IKNA, IOR, ME, MREO, MURA, NSTS, PARR, RPTX, SEG, SHCO, THRD | Banking, Biotechnology, REITs, small caps, special situations, value | Manager holds extensive broken biotech basket including companies that have halted development and are pursuing strategic alternatives or liquidations. These biotechs trade at significant discounts to net cash with potential for Tang-style buyouts or liquidations. | IGT EHAB SHCO NSTS IOR CKX THRD RPTX MURA EPIX ATHA |
View |
| 2024 Q4 | Dec 31, 2024 | Clark Street Value | - | -6.4% | ACR, ALVR, ATHA, AVTE, CKX, CMCT, EHAB, ENZ, EPIX, GRBK, HHH, HLVX, HMST, IKNA, INBX, LMNR, MREO, PARR, SEG | Biotechnology, Liquidations, M&A, real estate, special situations, spinoffs, value | Multiple SPAC-related investments including reverse merger situations where biotech companies are merging with private entities. These transactions often include special dividends, CVRs, and oversubscribed PIPEs that can create value for existing shareholders. | View | |
| 2024 Q3 | Oct 24, 2024 | Curreen Capital | 0.9% | 1.9% | AAP, CACC, EHAB, ENR.DE, FOUR.L, FTDR, GETB.L, NILB.ST, PLUX.PA, VFC | contrarian, Quality, small caps, spinoffs, Turnarounds, value | The fund focuses on buying quality businesses while they are temporarily out of favor in the stock market, describing their holdings as ugly ducklings that often languish for months before the market recognizes their value. The strategy involves starting small and buying more as stock prices drop to predetermined discounts. | VFC ENR.DE NILB.ST GETB.L FTDR EHAB CACC |
View |
| 2024 Q2 | Jul 23, 2024 | Curreen Capital | 0.9% | 1.9% | ADV, CACC, DND.TO, EHAB, FTDR, GETB.L, NILB.ST, SOLV, VFC | distressed, small caps, special situations, spinoffs, Turnarounds, value | Manager focuses on spinoff opportunities, specifically Solventum (spun from 3M) and Enhabit (spun from Encompass Health). These spinoffs typically face temporary challenges while establishing independence, creating attractive entry points for patient capital. | VFC EHAB DND.TO SOLV |
View |
| 2025 Q1 | Apr 24, 2025 | Curreen Capital | -4.7% | -4.7% | AAP, CACC, EHAB, ENR.DE, FTDR, GETB.L, HAVAS.PA, NILB.ST, VFC | Europe, small caps, spinoffs, Turnarounds, value | Manager focuses heavily on recent spinoffs like Havas (spun from Vivendi in December 2024) and Enhabit (spun from Encompass Health in July 2022). Notes that in market downturns, recent spinoffs are often sold aggressively, creating attractive opportunities. | HAVAS.AS |
View |
| 2022 Q4 | Jan 31, 2023 | Aristotle Small Cap Equity Fund | 7.3% | 9.4% | ADEA, AIMC, ASC, CALM, DBI, EHAB, SAF, VVI, XPER | - | View | ||
| 2023 Q4 | Jan 26, 2024 | Curreen Capital | 0.9% | 1.9% | AAP, ADV, CACC, CCC.L, DND.TO, EHAB, FTDR, GETB.L, KAMBI.ST, LNK.AX, NILB.ST, VFC | Cash, contrarian, Opportunistic, Quality, small caps, value | Manager follows a disciplined value strategy, buying excellent businesses at meaningful discounts to downside valuation. The fund takes advantage of market weakness to purchase quality companies trading at ridiculously low prices, with positions bought 33-65% below recent highs. | NILB.ST LNK.AX GETB.L FTDR CACC ADV |
View |
| 2024 Q4 | Jan 17, 2025 | Curreen Capital | 5.7% | 7.7% | AAP, CACC, EHAB, ENR.DE, FTDR, GETB.L, JXN, KAMBI.ST, NILB.ST, TNET, TRUE-B.ST, VFC | Automotive, healthcare, small caps, Turnarounds, undervalued, value | Manager focuses on buying good businesses at attractive prices below conservative valuation estimates. Portfolio consists of undervalued companies trading at significant discounts to intrinsic value. Strategy emphasizes attractive upside-to-downside ratios across holdings. | ENR.DE NILB.ST FTDR VFC TNET EHAB AAP GETB.L CACC |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Fund Letters | Curreen Capital | Enhabit Inc | Health Care | Health Care Services | Bull | NYSE | Healthcare services, Home Healthcare, Hospice, Medicare, Proxy Contest, spinoff, turnaround | View Pitch |
| Apr 13, 2026 | Fund Letters | Curreen Capital | Enhabit | Health Care | Health Care Services | Bull | NYSE | Distressed, Healthcare services, Home Healthcare, Hospice, Medicare, spinoff, turnaround, Value | View Pitch |
| Apr 13, 2026 | Fund Letters | Curreen Capital | Enhabit | Health Care | Health Care Services | Bull | NYSE | Healthcare services, Home Healthcare, Hospice, Medicare, spinoff, turnaround, Value | View Pitch |
| Dec 5, 2025 | Fund Letters | Pearu Põld | Enhabit, Inc. | Health Care | Health Care Services | Bull | NYSE | deleveraging, Home-Health, Hospice, Reimbursement, spinoff | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||